A20 as a Potential Therapeutic Target for COVID‐19
ABSTRACT Background Coronavirus disease 2019 (COVID‐19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), is a major concern due to its astonishing prevalence and high fatality rate, especially among elderly people. Patients suffering from COVID‐19 may exhibit immunosuppre...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-01-01
|
| Series: | Immunity, Inflammation and Disease |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/iid3.70127 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832087076158308352 |
|---|---|
| author | Yongyao Wu Lilan He Rong Li Jiuxuan Li Qing Zhao Bin Shao |
| author_facet | Yongyao Wu Lilan He Rong Li Jiuxuan Li Qing Zhao Bin Shao |
| author_sort | Yongyao Wu |
| collection | DOAJ |
| description | ABSTRACT Background Coronavirus disease 2019 (COVID‐19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), is a major concern due to its astonishing prevalence and high fatality rate, especially among elderly people. Patients suffering from COVID‐19 may exhibit immunosuppression in the initial stage of infection, while a cytokine storm can occur when the disease progresses to a severe stage. This inopportune immune rhythm not only makes patients more susceptible to the virus but also leads to numerous complications resulting from the excessive production of inflammatory factors. A20, which is widely accepted as a pivotal regulator of inflammation, has been shown to be implicated in the processes of antiviral responses and immunosuppression. Thus, A20 may participate in regulating the pathological processes of COVID‐19. Methods This narrative literature review summarizes recent evidence on the mechanisms of A20 in regulating the pathological processes of COVID‐19. We also downloaded single‐cell RNA‐seq data sets from healthy individuals and patients with varying severities of COVID‐19 from the NCBI GEO database to further dissect A20's regulatory mechanisms of these intricate cytokine pathways that are closely associated with SARS‐CoV‐2 infection. Results A20 might be one of the most critical anti‐infectious and anti‐inflammatory factors involved in the pathogenesis of COVID‐19. It effectively suppresses the immune damage and inflammatory storm caused by viral infection. Conclusions Understanding the relationship between A20‐regulated signaling pathways and pathological processes of COVID‐19 can provide insight into potential targets for intervention. Precise regulation of A20 to induce antiviral activity and an anti‐inflammatory response could mediate the pathogenesis of COVID‐19 and could become an effective treatment. |
| format | Article |
| id | doaj-art-fa50b478038d4cd7a24e29c312b4b4f4 |
| institution | Kabale University |
| issn | 2050-4527 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Immunity, Inflammation and Disease |
| spelling | doaj-art-fa50b478038d4cd7a24e29c312b4b4f42025-02-06T07:50:38ZengWileyImmunity, Inflammation and Disease2050-45272025-01-01131n/an/a10.1002/iid3.70127A20 as a Potential Therapeutic Target for COVID‐19Yongyao Wu0Lilan He1Rong Li2Jiuxuan Li3Qing Zhao4Bin Shao5State Key Laboratory of Oral Diseases and National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology Sichuan University Chengdu ChinaState Key Laboratory of Oral Diseases and National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology Sichuan University Chengdu ChinaState Key Laboratory of Oral Diseases and National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology Sichuan University Chengdu ChinaLaboratory of Radiation Biology, Laboratory Medicine Centre, Department of Blood Transfusion The Second Affiliated Hospital Army Military Medical University Chongqing ChinaState Key Laboratory of Oral Diseases and National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology Sichuan University Chengdu ChinaState Key Laboratory of Oral Diseases and National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology Sichuan University Chengdu ChinaABSTRACT Background Coronavirus disease 2019 (COVID‐19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), is a major concern due to its astonishing prevalence and high fatality rate, especially among elderly people. Patients suffering from COVID‐19 may exhibit immunosuppression in the initial stage of infection, while a cytokine storm can occur when the disease progresses to a severe stage. This inopportune immune rhythm not only makes patients more susceptible to the virus but also leads to numerous complications resulting from the excessive production of inflammatory factors. A20, which is widely accepted as a pivotal regulator of inflammation, has been shown to be implicated in the processes of antiviral responses and immunosuppression. Thus, A20 may participate in regulating the pathological processes of COVID‐19. Methods This narrative literature review summarizes recent evidence on the mechanisms of A20 in regulating the pathological processes of COVID‐19. We also downloaded single‐cell RNA‐seq data sets from healthy individuals and patients with varying severities of COVID‐19 from the NCBI GEO database to further dissect A20's regulatory mechanisms of these intricate cytokine pathways that are closely associated with SARS‐CoV‐2 infection. Results A20 might be one of the most critical anti‐infectious and anti‐inflammatory factors involved in the pathogenesis of COVID‐19. It effectively suppresses the immune damage and inflammatory storm caused by viral infection. Conclusions Understanding the relationship between A20‐regulated signaling pathways and pathological processes of COVID‐19 can provide insight into potential targets for intervention. Precise regulation of A20 to induce antiviral activity and an anti‐inflammatory response could mediate the pathogenesis of COVID‐19 and could become an effective treatment.https://doi.org/10.1002/iid3.70127A20COVID‐19immunosuppressioninflammatory responseSTING |
| spellingShingle | Yongyao Wu Lilan He Rong Li Jiuxuan Li Qing Zhao Bin Shao A20 as a Potential Therapeutic Target for COVID‐19 Immunity, Inflammation and Disease A20 COVID‐19 immunosuppression inflammatory response STING |
| title | A20 as a Potential Therapeutic Target for COVID‐19 |
| title_full | A20 as a Potential Therapeutic Target for COVID‐19 |
| title_fullStr | A20 as a Potential Therapeutic Target for COVID‐19 |
| title_full_unstemmed | A20 as a Potential Therapeutic Target for COVID‐19 |
| title_short | A20 as a Potential Therapeutic Target for COVID‐19 |
| title_sort | a20 as a potential therapeutic target for covid 19 |
| topic | A20 COVID‐19 immunosuppression inflammatory response STING |
| url | https://doi.org/10.1002/iid3.70127 |
| work_keys_str_mv | AT yongyaowu a20asapotentialtherapeutictargetforcovid19 AT lilanhe a20asapotentialtherapeutictargetforcovid19 AT rongli a20asapotentialtherapeutictargetforcovid19 AT jiuxuanli a20asapotentialtherapeutictargetforcovid19 AT qingzhao a20asapotentialtherapeutictargetforcovid19 AT binshao a20asapotentialtherapeutictargetforcovid19 |